Antibodies to <i>Escherichia coli</i> Outer Membrane Porin C in the Absence of Anti–<i>Saccharomyces cerevisiae</i> Antibodies and Anti‐neutrophil Cytoplasmic Antibodies Are an Unreliable Marker of Crohn Disease and Ulcerative Colitis

Davis, Michael K.; Andres, Joel M.; Jolley, Christopher D.; Novak, Donald A.; Haafiz, Allah; González‐Peralta, Regino P.

doi:10.1097/mpg.0b013e31812f7f6e

Cited by 17 publications

(15 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibodies directed against the outer membrane porin C transport protein of the Escherichia coli (Anti-OmpC antibody) were reported in 55% of adults and 24% of children with CD [26,27]. However, it is unreliable in identifying children with IBD in the absence of ASCA and pANCA antibodies [28]. The other outer membrane protein antibody is the antibody against Bacteroides caccae TonB-linked outer membrane protein (OmpW antibody) that was reported in 61% of children with CD and 42% of children with UC [29].…”

Section: Discussionmentioning

confidence: 95%

Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia

Saadah

Al-Mughales

2013

Arab Journal of Gastroenterology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 95%

Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia

Saadah

Al-Mughales

2013

Arab Journal of Gastroenterology

View full text Add to dashboard Cite

“…Eight of 117 individuals underwent anti-CBir1 antibody testing due to its late addition to commercially available panels. Positive tests were defined as values greater than assay reference values, similar to methodology used in prior studies 12;13 . For ASCA, a positive IgA or IgG indicated a positive result.…”

Section: Methodsmentioning

confidence: 99%

Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis

Sura

Ahmed

Cheifetz

et al. 2014

Journal of Clinical Gastroenterology

View full text Add to dashboard Cite

Goals and Background Inflammatory bowel disease (IBD) serology testing is often used in patients with indeterminate colitis (IC) to help distinguish between ulcerative colitis (UC) and Crohn’s disease (CD). We investigated the performance of serology testing in predicting future diagnosis in this setting. Study Observational study of individuals with IC at a single center who underwent IBD serology testing (pANCA, ASCA and anti-OmpC) and had at least 12 months follow-up from time of serology result. Results 117 individuals with IC and 1 year follow-up data were enrolled. All IC patients had endoscopic and histologic evidence of colitis at enrollment. One year after serology testing, 58 (50%) individuals with IC were diagnosed with UC, 49 (42%) with CD, and 10 (9%) remained labeled with IC. The sensitivity/specificity of an initial positive pANCA for a subsequent diagnosis of UC was 78%/44%. For ASCA and anti-OmpC, the results were 18%/84% and 27%/75%, respectively, for a subsequent diagnosis of CD. A positive pANCA test was associated with a likelihood ratio (LR) of 1.4 (95% CI: 1.1–1.8) for a subsequent diagnosis of UC at 1 year. Neither positive ASCA (LR 1.1; 95% CI: 0.5–2.5) nor anti-OmpC (LR 1.1; 95% CI: 0.6–2.0) was associated with a subsequent diagnosis CD in patients with IC. Conclusions The disease phenotype in the majority of individuals initially labeled with IC evolved to be more consistent with either UC or CD on follow-up. pANCA, ASCA, and anti-OmpC, individually, were of limited utility in predicting a patient’s subsequent disease phenotype.

show abstract

“…The reverse profile was even less helpful for definitive diagnosis. In IBD-U, a significant number of patients seem to have negative serology, but this provides no help in the diagnostic process (49 (47,(52)(53)(54); all these markers are nonspecific and can be detected in patients with other diseases.…”

Section: Serology and Subtype Of Ibdmentioning

confidence: 99%

ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents

Levine

Koletzko

Turner

et al. 2014

J. pediatr. gastroenterol. nutr.

1,058

787

View full text Add to dashboard Cite

Background: The diagnosis of pediatric-onset inflammatory bowel disease (PIBD) can be challenging in choosing the most informative diagnostic tests and correctly classifying PIBD into its different subtypes. Recent advances in our understanding of the natural history and phenotype of PIBD, increasing availability of serological and fecal biomarkers, and the emergence of novel endoscopic and imaging technologies taken together have made the previous Porto criteria for the diagnosis of PIBD obsolete. Methods: We aimed to revise the original Porto criteria using an evidencebased approach and consensus process to yield specific practice recommendations for the diagnosis of PIBD. These revised criteria are based on the Paris classification of PIBD and the original Porto criteria while

show abstract

Antibodies to Escherichia coli Outer Membrane Porin C in the Absence of Anti–Saccharomyces cerevisiae Antibodies and Anti‐neutrophil Cytoplasmic Antibodies Are an Unreliable Marker of Crohn Disease and Ulcerative Colitis

Abstract: Anti-OmpC, in the absence of ASCA and ANCA, is a serological pattern noted in a subset of medically complex cases in children and young adults without CD or UC.

Cited by 17 publications

References 6 publications

Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia

Serological markers of inflammatory bowel disease in children from the Western region of Saudi Arabia

Characteristics of Inflammatory Bowel Disease Serology in Patients With Indeterminate Colitis

ESPGHAN Revised Porto Criteria for the Diagnosis of Inflammatory Bowel Disease in Children and Adolescents

Contact Info

Product

Resources

About